Illumina, Inc. $ILMN Holdings Boosted by Casdin Capital LLC

Casdin Capital LLC boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 14.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 600,000 shares of the life sciences company’s stock after buying an additional 75,000 shares during the quarter. Illumina makes up about 4.9% of Casdin Capital LLC’s holdings, making the stock its 7th biggest holding. Casdin Capital LLC’s holdings in Illumina were worth $78,696,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Illumina by 17.5% in the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after buying an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co acquired a new position in Illumina during the 3rd quarter worth $2,319,000. Capital World Investors grew its stake in Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. Nordea Investment Management AB lifted its holdings in Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after buying an additional 911,843 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in Illumina during the 3rd quarter worth about $1,827,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN opened at $159.09 on Thursday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $177.22. The stock has a market cap of $24.07 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 3.08 and a beta of 1.50. The business’s 50 day moving average is $143.81 and its 200-day moving average is $135.76. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. Illumina’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current year.

Insider Buying and Selling at Illumina

In related news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the transaction, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the transaction, the director owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This represents a 7.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,003,154 shares of company stock worth $155,600,208 in the last ninety days. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ILMN. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Citigroup upped their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Hold” and an average price target of $142.13.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.